Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:PMN)

ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights

GlobeNewswire 1 day ago

ProMIS Neurosciences to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

GlobeNewswire 3 days ago

ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference

GlobeNewswire October 30, 2024

ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences

GlobeNewswire September 12, 2024

ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire September 5, 2024

ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights

GlobeNewswire August 8, 2024

ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology

GlobeNewswire August 6, 2024

ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024

GlobeNewswire August 1, 2024

ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference

GlobeNewswire July 30, 2024
View More News ››

Opinion & Analysis (NDAQ:PMN)

Building a Better Covid-19 Antibody Test

Streetwise Reports May 7, 2020

Could There Finally Be an Effective Treatment for Alzheimer's Disease?

Streetwise Reports November 7, 2019

Alzheimer’s Solution Shows Promise after Big Pharma’s Cure Fails

Stockhouse Editorial March 28, 2019

Biotech Releases White Paper on Alzheimer's Disease Candidate

Streetwise Reports August 2, 2018

Preclinical Data for Alzheimer's Therapy to Be Presented at AAIC

Streetwise Reports July 11, 2018

Candidates Targeting Parkinson's Disease and ALS Advance in Discovery Phase

Streetwise Reports June 28, 2018
View More Opinion ››

Bullboard Posts (NDAQ:PMN)

Financings

If the 6 months interm results do not bring good results then the share price will surely be below 2 dollars and they will not be able to...
goldtech - 12 hours ago

Prothena PRX012 Alzheimers

Looks like they are kicking the can down the road on topline results. Were supposed to see phase 1 results by the end of 2023 then 2024...
FarmerBetsy - 2 days ago

Cognitive outcomes

Now that is efficacy for those that want to know what we will show and in the 6 months interm results.
goldtech - 4 days ago

RE:RE:Poster presentation October 30th??

"The data allowed us to establish dosing schedule and dosing levels for a 100 patient, 12-month study of PMN310 in MCI due to AD and...
Gbathat - 5 days ago

RE:Poster presentation October 30th??

Poster presentation is now available. Thank you Promis! https://d1io3yog0oux5.cloudfront.net/_43333ef1871b a38be6409dc30d48dec9...
Speyeder999 - 5 days ago

RE:From last june the 20th.

There was a guy here under the name of Retiredcop , he was a real Neil Cashman's fan , i think he could have died for him , we have...
Alex1726 - 7 days ago
View more Bullboard ››

Tidal Care Inc.

Tidal Care Inc.

Tidal Care aims to be a high-compliance supplier of finished, formulated Psilocybin- and MDMA-based drug products to the ...
View More »